{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:31:15Z","timestamp":1786487475204,"version":"build-2736575974"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001459","name":"Government of Singapore Ministry of Education","doi-asserted-by":"publisher","award":["RT17\/23"],"award-info":[{"award-number":["RT17\/23"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NRF-CRP30-2023-0004"],"award-info":[{"award-number":["NRF-CRP30-2023-0004"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.biomaterials.2026.124415","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:04:16Z","timestamp":1782774256000},"page":"124415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Peptide coacervate\u2013mediated siRNA delivery for dual PD-1\/PD-L1 blockade to enhance colorectal cancer immunotherapy"],"prefix":"10.1016","volume":"335","author":[{"given":"Zilin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4946-3802","authenticated-orcid":false,"given":"Vaibavi","family":"Ramanujam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3459-3591","authenticated-orcid":false,"given":"Syed","family":"Maricar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congxi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8279-577X","authenticated-orcid":false,"given":"Anastasia","family":"Shebanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9586-0913","authenticated-orcid":false,"given":"Bertrand","family":"Czarny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-8170","authenticated-orcid":false,"given":"Ali","family":"Miserez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biomaterials.2026.124415_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"16","key":"10.1016\/j.biomaterials.2026.124415_bib2","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.3390\/ijms22168470","article-title":"Tumor-associated macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124415_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102333","article-title":"Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases","volume":"104","author":"Huang","year":"2019","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124415_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124415_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124415_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124415_bib7","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1021\/acsnano.0c09514","article-title":"In vivo T cell-targeting nanoparticle drug delivery systems: considerations for rational design","volume":"15","author":"Cevaal","year":"2021","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124415_bib8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124415_bib9","article-title":"PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"issue":"21","key":"10.1016\/j.biomaterials.2026.124415_bib10","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-Cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124415_bib11","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1167\/iovs.07-1606","article-title":"PD-L1: PD-1 interaction contributes to the functional suppression of T-Cell responses to human uveal melanoma cells in vitro","volume":"49","author":"Yang","year":"2008","journal-title":"Investig. Opthalmology Vis. Sci."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124415_bib12","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.biomaterials.2026.124415_bib13","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3389\/fimmu.2020.01624","article-title":"Colorectal cancer immunotherapy: options and strategies","volume":"11","author":"Johdi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124415_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124415_bib15","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1002\/onco.13887","article-title":"Systematic review of PD-1\/PD-L1 inhibitors in oncology: from personalized medicine to public health","volume":"26","author":"Chang","year":"2021","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.biomaterials.2026.124415_bib16","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6382","key":"10.1016\/j.biomaterials.2026.124415_bib17","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124415_bib18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124415_bib19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the Anti-PD-1 and Anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124415_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12951-023-01966-4","article-title":"Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy","volume":"21","author":"Liu","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biomaterials.2026.124415_bib21","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 distribution and perspective for cancer immunotherapy\u2014blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Immunol."},{"issue":"26","key":"10.1016\/j.biomaterials.2026.124415_bib22","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124415_bib23","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.7150\/thno.121865","article-title":"Curcumin coacervates for supramolecular-interaction-responsive cytosolic siRNA delivery to enhance pyroptosis","volume":"16","author":"Cheng","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.biomaterials.2026.124415_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-Based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124415_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-Based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2026.124415_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115306","article-title":"Advancing cancer immunotherapy through siRNA-Based gene silencing for immune checkpoint blockade","volume":"209","author":"Choi","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2026.124415_bib27","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.2147\/IJN.S436038","article-title":"A comprehensive review of small interfering RNAs (siRNAs): mechanism, therapeutic targets, and delivery strategies for cancer therapy","volume":"18","author":"Zhang","year":"2023","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124415_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12929-023-00981-9","article-title":"Small interfering RNA (siRNA)-Based therapeutic applications against viruses: principles, potential, and challenges","volume":"30","author":"Kang","year":"2023","journal-title":"J. Biomed. Sci."},{"issue":"21","key":"10.1016\/j.biomaterials.2026.124415_bib29","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/bph.15972","article-title":"Small interfering RNA: discovery, pharmacology and clinical development\u2014an introductory review","volume":"180","author":"Ranasinghe","year":"2023","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124415_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124415_bib31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1021\/mp900093r","article-title":"Biological barriers to therapy with antisense and siRNA oligonucleotides","volume":"6","author":"Juliano","year":"2009","journal-title":"Mol. Pharm."},{"issue":"7228","key":"10.1016\/j.biomaterials.2026.124415_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature07758","article-title":"The promises and pitfalls of RNA-Interference-Based therapeutics","volume":"457","author":"Castanotto","year":"2009","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124415_bib33","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1007\/s12274-018-2099-4","article-title":"Design of synthetic materials for intracellular delivery of RNAs: from siRNA-Mediated gene silencing to CRISPR\/Cas gene editing","volume":"11","author":"Miller","year":"2018","journal-title":"Nano Res."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124415_bib34","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1021\/acs.molpharmaceut.9b00826","article-title":"PLGA nanoparticles codelivering siRNAs against programmed cell death Protein-1 and its ligand gene for suppression of Colon tumor growth","volume":"16","author":"Kwak","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2026.124415_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.614365","article-title":"PD-L1 siRNA theranostics with a dextran nanoparticle highlights the importance of nanoparticle delivery for effective tumor PD-L1 downregulation","volume":"10","author":"Pacheco-Torres","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124415_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1208\/s12249-021-01933-y","article-title":"PD-1 siRNA-Encapsulated solid lipid nanoparticles downregulate PD-1 expression by macrophages and inhibit tumor growth: PD-1 siRNA-Encapsulated solid lipid nanoparticles","volume":"22","author":"Hanafy","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124415_bib37","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2217\/nnm.10.107","article-title":"Engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances","volume":"5","author":"Buse","year":"2010","journal-title":"Nanomed"},{"issue":"20","key":"10.1016\/j.biomaterials.2026.124415_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201700759","article-title":"Membrane fusion mediated intracellular delivery of lipid bilayer coated mesoporous silica nanoparticles","volume":"6","author":"Yang","year":"2017","journal-title":"Adv. Healthc. Mater."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124415_bib39","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1039\/C0CS00018C","article-title":"Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies","volume":"40","author":"Khlebtsov","year":"2011","journal-title":"Chem. Soc. Rev."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124415_bib40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.addr.2009.11.008","article-title":"Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications","volume":"62","author":"Fadeel","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124415_bib41","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1021\/acs.bioconjchem.8b00369","article-title":"Glucose-responsive peptide coacervates with high encapsulation efficiency for controlled release of insulin","volume":"29","author":"Lim","year":"2018","journal-title":"Bioconjug. Chem."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124415_bib42","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1021\/jacsau.5c01164","article-title":"Phase-separated coacervates of low-molecular-weight compounds for cytosolic delivery and disease treatment","volume":"5","author":"Bao","year":"2025","journal-title":"JACS Au"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124415_bib43","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41557-021-00854-4","article-title":"Phase-separating peptides for direct cytosolic delivery and redox-activated release of macromolecular therapeutics","volume":"14","author":"Sun","year":"2022","journal-title":"Nat. Chem."},{"issue":"17","key":"10.1016\/j.biomaterials.2026.124415_bib44","doi-asserted-by":"crossref","first-page":"16597","DOI":"10.1021\/acsnano.3c02669","article-title":"Redox-responsive phase-separating peptide as a universal delivery vehicle for CRISPR\/Cas9 genome editing machinery","volume":"17","author":"Sun","year":"2023","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124415_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54463-z","article-title":"Phase-separating peptide coacervates with programmable material properties for universal intracellular delivery of macromolecules","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124415_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biomaterials.2026.124415_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121339","article-title":"In situ T-Cell transfection by Anti-CD3-Conjugated lipid nanoparticles leads to T-Cell activation, migration, and phenotypic shift","volume":"281","author":"Kheirolomoom","year":"2022","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124415_bib48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124415_bib49","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41467-017-01830-8","article-title":"T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity","volume":"8","author":"Schmid","year":"2017","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124415_bib50","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1021\/acsnano.5b02796","article-title":"Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles","volume":"9","author":"Ramishetti","year":"2015","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124415_bib51","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1021\/bc2006219","article-title":"T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles","volume":"23","author":"Lee","year":"2012","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124415_bib52","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41467-017-00481-z","article-title":"Endocytic sorting motif interactions involved in nef-mediated downmodulation of CD4 and CD3","volume":"8","author":"Manrique","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124415_bib53","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/tra.12272","article-title":"Phenothiazine\u2010derived antipsychotic drugs inhibit dynamin and clathrin\u2010mediated endocytosis","volume":"16","author":"Daniel","year":"2015","journal-title":"Traffic"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124415_bib54","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0223-5234(03)00100-4","article-title":"An overview of inhibitors of Na+\/H+ exchanger","volume":"38","author":"Masereel","year":"2003","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124415_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/15592324.2021.1920192","article-title":"Formins control dynamics of F-Actin in the central cell of Arabidopsis thaliana","volume":"16","author":"Ali","year":"2021","journal-title":"Plant Signal. Behav."},{"issue":"13","key":"10.1016\/j.biomaterials.2026.124415_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108884","article-title":"Formin Nanoclustering-Mediated actin assembly during plant flagellin and DSF signaling","volume":"34","author":"Ma","year":"2021","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124415_bib57","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbamcr.2008.12.018","article-title":"The role of formins in filopodia formation","volume":"1803","author":"Mellor","year":"2010","journal-title":"Biochim. Biophys. Acta BBA - Mol. Cell Res."},{"issue":"42","key":"10.1016\/j.biomaterials.2026.124415_bib58","article-title":"Cellular uptake of phase\u2010separating peptide coacervates","volume":"11","author":"Shebanova","year":"2024","journal-title":"Adv. Sci."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124415_bib59","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124415_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110400","article-title":"IFN\u03b3-Induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling","volume":"97","author":"Padmanabhan","year":"2022","journal-title":"Cell. Signal."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124415_bib61","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/1873-3468.15083","article-title":"IFN \u03b3 and TNF \u03b1 drive an inflammatory secretion profile in cancer\u2010associated fibroblasts from human non\u2010small cell lung cancer","volume":"599","author":"Koppensteiner","year":"2025","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124415_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12441","article-title":"Anti-cancer therapy with TNF\u03b1 and IFN\u03b3: a comprehensive review","volume":"51","author":"Shen","year":"2018","journal-title":"Cell Prolif."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124415_bib63","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: Rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124415_bib64","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (checkMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6349","key":"10.1016\/j.biomaterials.2026.124415_bib65","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124415_bib66","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1016\/j.apsb.2024.05.028","article-title":"Mitochondrial metabolism blockade nanoadjuvant reversed immune-resistance microenvironment to sensitize albumin-bound paclitaxel-based chemo-immunotherapy","volume":"14","author":"Zhou","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biomaterials.2026.124415_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123335","article-title":"Overcoming radiation-induced PD-L1 and COX-2 upregulation by nitric oxide gas nanogenerator to sensitize radiotherapy of lung cancer","volume":"321","author":"Hu","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2026.124415_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101323","article-title":"Nanoparticles-mediated mitochondrial relocation of lipid-lowering drugs shape energy metabolism to conquer acquired immune resistance","volume":"84","author":"Li","year":"2026","journal-title":"Drug Resist. Updates"},{"issue":"40","key":"10.1016\/j.biomaterials.2026.124415_bib69","doi-asserted-by":"crossref","first-page":"35724","DOI":"10.1021\/acsnano.5c12015","article-title":"Hierarchical structural organization in bioinspired peptide coacervate microdroplets","volume":"19","author":"Lim","year":"2025","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124415_bib70","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.62347\/BRTO3272","article-title":"Unveiling the nexus of P53 and PD-L1: insights into immunotherapy resistance mechanisms in hepatocellular carcinoma","volume":"15","author":"Zhang","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124415_bib71","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"15","key":"10.1016\/j.biomaterials.2026.124415_bib72","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.3390\/cancers17152547","article-title":"IFN \u03b3 and the IFN \u03b3 signaling pathways in merkel cell carcinoma","volume":"17","author":"Song","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2026.124415_bib73","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124415_bib74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4049\/jimmunol.1601145","article-title":"Intratumoral delivery of immunotherapy\u2014Act locally, think globally","volume":"198","author":"Aznar","year":"2017","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124415_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006774","article-title":"Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1\/2 clinical trial","volume":"11","author":"G\u00f6genur","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124415_bib76","article-title":"Advancing cancer immunotherapy through emerging intratumoral delivery and biomedical imaging technologies","volume":"24","author":"Choi","year":"2024","journal-title":"Mater. Today Adv."},{"issue":"23","key":"10.1016\/j.biomaterials.2026.124415_bib77","doi-asserted-by":"crossref","first-page":"8436","DOI":"10.3390\/jcm14238436","article-title":"Establishing a salvage endoscopic electroporation (SEE) service for colorectal cancer: the king's protocol for clinical implementation","volume":"14","author":"Adeyeye","year":"2025","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124415_bib78","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.3390\/jcm11102745","article-title":"Electrochemotherapy of primary Colon rectum cancer and local recurrence: case report and prospective analysis","volume":"11","author":"Rega","year":"2022","journal-title":"J. Clin. Med."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226004394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226004394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:11:55Z","timestamp":1786486315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226004394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":78,"alternative-id":["S0142961226004394"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124415","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide coacervate\u2013mediated siRNA delivery for dual PD-1\/PD-L1 blockade to enhance colorectal cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"124415"}}